Nimacimab
1 paper
- Human trial1
Latest
1 in 12 monthsADA Scientific Sessions 2026 Abstract
Preliminary Data on Continuing Weight Loss at 52 Weeks and Durable Weight Loss Off Therapy with Nimacimab, a CB1R Antibody, in Combination with Semaglutide
Randomised trial in 136 peopleSemaglutide